What do data in monoinfection mean in relation to co-infection?

Slides:



Advertisements
Similar presentations
Management of Chronic Hepatitis C in 2013
Advertisements

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
HCV: Treat now or Defer Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL JUNE 19,
Treatment of Hepatitis C in patients with thalassaemia
Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 TURQUOISE-II Phase 3 Treatment.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
Hepatitis web study Hepatitis web study Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Phase 2b Treatment Naïve and Treatment Experienced.
Compensated Cirrhosis
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:
Controversies: Lead in or no lead in ? PRO Controversies: Lead in or no lead in ? PRO Lawrence Serfaty Hôpital Saint-Antoine Paris 5th Paris Hepatitis.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Management of Patients Co- infected with HCV and HIV: A Close Look at the Role for DAAs Susanna Naggie, MD Assistant Professor of Medicine Division of.
Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin Paul Y Kwo, MD Professor of Medicine Medical Director,
Xavier Forns, MD Liver Unit, Hospital Clínic IDIBAPS and CIBREHD Barcelona, Octubre 2013 Tratamiento de poblaciones especiales Curso de Residentes AEEH.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.
Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.
How to optimize treatment of G1 patients? Prof. G. K. K. Lau 2012.
Future treatment of patients with HCV cirrhosis Marc Bourlière Dept of Hepato-gastroenterology 5 th Paris Hepatitis Conference Saint Joseph Hospital, Marseille.
AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.
Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
Clinical case Laurent CASTERA 5th PHC, Paris, January Service d’Hépatologie Hôpital Beaujon, Université Paris-7, Clichy, France.
Hepatitis C Nonresponders
AASLD 2010 HCV Feedback October 29 - November 2, 2010 Boston, Massachusetts Dr Allister J Grant Consultant Hepatologist Leicester Liver Unit.
Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.
Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:
Hepatitis web study Hepatitis web study Simeprevir versus Telaprevir with PR in GT1 ATTAIN Trial Phase 3 Treatment Experienced Reddy KR, et al. Lancet.
36 year old HCV+ woman, Risk factor: occasional IVDU 15 years ago First treatment with PEG-IFN/RBV in 2002 –only qualitative PCR available : positive at.
Daniel Dhumeaux, Henri Mondor hospital Créteil, France HCV compassionate use programme The French experience Amsterdam, April.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.
SOF + RBV GT2 Japanese SOF + RBV Open-label Japanese SOF + RBV Study: SOF + RBV in genotype 2  Design W12 Japanese patients ≥ 20 years Chronic HCV infection.
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
PHOTON-2 Study: SOF + RBV in HCV-HIV co-infection
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection
Phase 3b Treatment-Naive
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 2 Treatment Naïve HIV Coinfection
HIV/HCV Co-Infection Case
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE
Boceprevir in Treatment Naive SPRINT-2
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
HCV Protease Inhibitors in Clinical Practice
Design W12 Randomisation * Open-label
ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.
Phase 3 Treatment-Naïve and Treatment-Experienced
LEPTON Study: SOF/VEL + GS-9857 genotype 1 or 3 Phase II
PI-Based HCV-1 Therapy: Reasons to Hold Off
Phase 2b Treatment Naïve and Treatment Experienced
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.
ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients
MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB
HCV Protease Inhibitors in Clinical Practice
New HCV therapies on the horizon
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
Why We Should Be Willing to Pay for Hepatitis C Treatment
SOF/VEL ± RBV in genotype 3 with compensated cirrhosis
Telaprevir in Treatment Experienced GT-1 PROVE3
Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study
Sequencing cohorts Open-label Design W8 W12 ≥ 18 years
Presentation transcript:

What do data in monoinfection mean in relation to co-infection?

Treatment of Chronic Hepatitis C

Telaprevir and Boceprevir SVR by patient Type

SVR Rates With BOC or TVR in GT1 Treatment-Experienced Patients

Futility Rules for BOC or TVR + PegIFN/RBV

Telaprevir + PR: Adverse Events

Boceprevir + PR: Adverse Events

Practical Strategies: Managing Anemia

Telaprevir: SVR Rates by RBV Dose Reduction in ADVANCE and ILLUMINATE

Boceprevir: SVR in Pts With Hb < 10 g/dL by EPO and/or RBV Dose Reduction

Adverse Effect Management: Anaemia

My patient (SS)

Accepted for Boceprevir EAP

Viral Response and Tolerability

Viral Response and Tolerability

King’s cohort n=20: adverse effects

New HCV agents : What are the possible challenges?

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.